Gabriel Tremblay, Health Economist

Health Economics: Communication and Strategy

Strategy

• Evaluation of necessary evidence for economic evaluation in early stages of development
• Gap analysis to evaluate what missing information and development needs
• Planning of health economic work, evidence development and analysis
• Planning of health economic endpoints and development (QALY, health outcomes, etc.)
• Review of economic analysis, participation in expert panels (research or evaluation)

Communication

• Develop communication materials, review and advise on communication in health economics

Health Economics and Pharmacoeconomics

• Analysis of drugs, medical devices, surgeries and other treatment options
• Sub-group analysis, personalized medicine economic analysis, niche analysis, and health economics research

Type of studies

• Cost-effectiveness analysis (CEA) with cost per unit of health as measured
• Cost-utility analysis (CUA) with cost per QALY
• Cost-minimization analysis (CMA)
• Budget Impact Analysis (BIA and BIM)
• Cost-consequence analysis (CCA)

Economic evaluation of social and health programs

Social programs

• Socio-economic evaluation of social and health programs
• Public health economics (vaccination, prevention, screening, etc.)
• Prevention economics and assessment of program efficacy

Type of studies

• Cost-benefit analysis (CBA) including willingness-to-pay analysis or monetization of specific impact
• Socio-economic analysis of programs with economic impact assessment or efficacy analysis of the programs with health and cost index
• Economic assessment of R&D and investment in healthcare and pharmaceutical industry (subsidies, investment, etc.)

Decision models, disease Modelling and Epidemiology

Epidemiology

• Patient flow and projection of patients
• Patients burden and health outcomes

Health Modelling

• Health states modeling and disease progression (Markov model...)
• Decision model (decision tree...) and discrete models
• Disease transmission modelling (infectious disease, epidemics and pandemics)
• Patient simulation modelling

Payers, patients and Evidence-base medicine

Payers

• Prospective claim analyses
• Medical need to fulfill

Patients

• Quality-of-life analysis
• Utility assessment with conjoint analysis to develop QALYs

Evidence-based medicine

• Indirect treatment comparison (ITC)
• Mixed treatment comparison (MTC)
• Meta-analysis
• Survival analysis
• Health outcomes statistics and analysis